Literature DB >> 23260183

[Prognostic factors in emphysematous pyelonephritis].

D Olvera-Posada1, A García-Mora, C Culebro-García, R Castillejos-Molina, M Sotomayor, G Feria-Bernal, F Rodríguez-Covarrubias.   

Abstract

OBJECTIVES: The purpose of this study is to analyze our experience with 18 cases of Emphysematous pyelonephritis (EPN) in a tertiary care center and describe our treatment strategy.
MATERIAL AND METHODS: Of 262 patients admitted with acute pyelonephritis, 18 had CT findings of EPN. The Wan and Huang classifications were used. We assessed the clinical, radiological, and therapeutic characteristics of these patients and investigated potential prognostic factors of mortality.
RESULTS: Between 2005 and 2010, 17 women and 1 man with EPN were treated. Mean age was 52.4 years. Diabetes was found in 66% and hypertension in 72%. The most common clinical findings were tachycardia (11), fever (11) and flank pain (9); 66% (12) presented with severe sepsis and 2 had septic shock. Acute renal injury developed in 61%. Nine patients were treated exclusively with conservative management; 5 had double J stenting, 3 had CT-guided PCD and 1 required nephrectomy after unsuccessful medical management. Mortality was 11%. Altered consciousness (P=.0001), multiple organ failure (P=.0004), hyperglycemia (P=.003) and elevated leukocyte count (> 20000 K) (P=.01) were more frequent among patients dying from EPN. No difference in mortality was found between patients managed conservatively and those undergoing invasive therapy.
CONCLUSIONS: Although rare, EPN should be suspected in patients with multiple comorbidities presenting with severe sepsis. Altered consciousness, multiple organ failure, hyperglycemia and elevated leukocyte count are poor prognosis indicators. Invasive management should be used judiciously and medical treatment can be a safe strategy in selected cases.
Copyright © 2012 AEU. Published by Elsevier España, S.L. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23260183     DOI: 10.1016/j.acuro.2012.03.021

Source DB:  PubMed          Journal:  Actas Urol Esp        ISSN: 0210-4806            Impact factor:   0.994


  6 in total

1.  What is the prognosis of emphysematous pyelonephritis associated with extended-spectrum beta-lactamases producing microorganisms?

Authors:  José Iván Robles-Torres; Marco Alberto Ocaña-Munguía; José Gustavo Arrambide-Herrera; Adrián Mauricio Martínez-Fernández; Rodrigo Romero-Mata; Lauro Salvador Gómez-Guerra
Journal:  Asian J Urol       Date:  2021-05-05

Review 2.  Emphysematous pyelonephritis: Time for a management plan with an evidence-based approach.

Authors:  Omar M Aboumarzouk; Owen Hughes; Krishna Narahari; Richard Coulthard; Howard Kynaston; Piotr Chlosta; Bhaskar Somani
Journal:  Arab J Urol       Date:  2013-11-19

3.  Emphysematous pyelonephritis in a diabetic patient with obstructed kidney.

Authors:  Piotr Kutwin; Tomasz Konecki; Zbigniew Jabłonowski
Journal:  Cent European J Urol       Date:  2014-06-23

4.  Emphysematous Pyelonephritis Case Series From South India.

Authors:  Mahesh Eswarappa; Sarita Suryadevara; Manns Manohar John; Mahesh Kumar; Sujeeth Bande Reddy; Mohammed Suhail
Journal:  Kidney Int Rep       Date:  2017-12-08

5.  Emphysematous Pyelonephritis Following Ureterovesical Reimplantation for Congenital Obstructive Megaureter. Pediatric Case Report and Review of the Literature.

Authors:  Vincenza Girgenti; Gloria Pelizzo; Salvatore Amoroso; Gregorio Rosone; Marco Di Mitri; Mario Milazzo; Salvatore Giordano; Rosaria Genuardi; Valeria Calcaterra
Journal:  Front Pediatr       Date:  2019-01-24       Impact factor: 3.418

6.  Mortality in emphysematous pyelonephritis: Can we reduce it further by using a protocol-based treatment? The results of a prospective study.

Authors:  Kalyanaram Kone; Naveen Thimiri Mallikarjun; M D R K Keerthi Rams
Journal:  Urol Ann       Date:  2022-01-20
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.